Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TM4SF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TM4SF1 LEL (Large Extracellular Loop) ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View TM4SF1 Products |
| Gene Delivery | TM4SF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to preserve native 4-TM conformation. |
View TM4SF1 Products |
| Benchmark Ab | Anti-TM4SF1 (Sequence of clinical-stage benchmark) Recombinant positive control antibody for validation assays. |
View TM4SF1 Products |
| Validator | TM4SF1 siRNA Set For target knockdown verification and assay specificity controls. |
View TM4SF1 Products |
| Related Target A | TM4SF4 Subfamily homolog. Critical for cross-reactivity and off-target safety screening. |
View TM4SF4 Products |
| Related Target B | TM4SF5 Subfamily homolog. Required for specificity profiling in L6 tetraspanin family. |
View TM4SF5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 4-TM target | Lentivirus premade particles for stable overexpressing cell lines. Essential for native-state FACS and cell-based assays. |
| Epitope Specificity (LEL vs SEL) | Recombinant TM4SF1 LEL (Large Extracellular Loop) Fc-fusion proteins strictly sequence-verified and expressed in HEK293. |
| Lack of Controls | Clinical-grade benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Sequence-specific TM4SF1 siRNA sets included for target validation and knockdown control. |
Live TM4SF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TM4SF1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to highly potent Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. TM4SF1 (Transmembrane 4 L6 Family Member 1) is highly overexpressed in a broad range of solid tumors—including pancreatic, lung, breast, and prostate cancers—as well as on tumor-associated vascular endothelial cells. This dual targeting of both tumor cells and tumor vasculature makes TM4SF1 an exceptionally attractive oncology target. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimized internalization kinetics and minimizing off-target toxicities within the L6 tetraspanin family.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Eisai, Academic Institutions | Solid Tumors (Pancreatic, NSCLC, Breast) | Internalization Assay (Need high-purity LEL-Fc and native conformation stable cell lines) |
| CAR-T Therapy | Biotech Startups, Clinical Centers | Refractory Solid Tumors, Metastatic Disease | Target Density & Specificity Validation (Need TM4SF1 vs TM4SF4/5 counter-screening) |
| Monoclonal/Bispecific Ab | Oncology-focused Biotechs | Tumor Angiogenesis, Metastasis Inhibition | Epitope Mapping & Blockade Assays (Need recombinant LEL-Fc proteins) |